INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study.

@article{Hamza2016INTRAVITREALII,
  title={INTRAVITREAL INFLIXIMAB IN REFRACTORY UVEITIS IN BEHCET'S DISEASE: A Safety and Efficacy Clinical Study.},
  author={Mostafa M E Hamza and Tamer A Macky and Mohamed Karim Sidky and Gaafar Mohamed Ragab and Mahmoud M. M. Soliman},
  journal={Retina},
  year={2016},
  volume={36 12},
  pages={2399-2408}
}
PURPOSE To assess the safety and efficacy of intravitreal infliximab (1 mg/0.05 mL) in patients with refractory posterior uveitis in Behcet's disease. METHODS Twenty patients were included in this study. Best corrected visual acuity (BCVA), vitreous haze (graded 0-4), vasculitis, retinitis, and papillopathy (presence or absence) were assessed at baseline, Day 1 and Week 2, 4, 6, 8, 12, and 18. Optical coherence tomography (OCT) central foveal thickness, fluorescein angiography, and flash… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 5 times. VIEW TWEETS